Jan 22, 2019, Fight Cancer Seminar - Redeye, Stockholm, Sweden
Feb 2-6, 2019, SLAS 2019, Washington D.C., USA
Fight Cancer Seminar - Redeye, Stockholm, Jan 22, 2019 > Webcast
BioInvent's Capital Markets Day, Stockholm, Sweden, Dec 10, 2018 > Presentation
Video from the CMD, Dec 10, 2018 > YouTube
BioInvent's KOL event, New York, Nov 6, 2018 > Webcast
BioInvent develops the next generation of immuno-oncology therapies
BioInvent is generating value for shareholders by employing its antibody and cancer biology expertise to identify antibodies with novel mechanisms-of-action and novel oncology targets. The Company employs this approach to generate therapeutic immuno-modulating antibodies that can be developed for a broad range of cancer indications. The Company plans to bring these antibodies to the clinic through its own resources and together with partners.
Immuno-oncology - a revolution in cancer treatment
The body’s immune defense is one of the most effective weapons to fight cancer. Development of new immuno-oncology drugs directing the immune defense against the tumour is expected to revolutionize the treatment.
Antibody therapy in focus
Pharmaceutical companies all around the world are working intensely to find antibodies that can counteract tumours growth and promote immune responses against cancer.
Five focus areas for our value creation
BioInvent develops antibody drugs that are effective, yet do not obstruct the normal functions of cells in the rest of the body. We aim to make cancer patients survive longer and improve their quality of life. Our business strategy is based on five solid pillars.
Bioinvent creates value by developing a risk-balanced portfolio of innovative oncology projects.
BioInvent’s drug candidate aims to resolve the problem of resistance to the current treatment of B-cell cancers. A phase I/II trial is ongoing in Non-Hodgkin’s lymphoma and chronic lymphocytic leukemia and a new study is expected to be launched in the first half of 2018.
A potential orphan drug undergoing a phase I/II trial in patients with medulloblastoma – a rare but potentially fatal type of pediatric brain tumor currently lacking efficient treatment.
A collaboration with Pfizer Inc. for the development and commercialization of new antibody therapies directed towards tumor associated myeloid cells.
BioInvent is currently developing antibodies specific for currently undetermined Treg targets and functions as well as for known targets.
At the end of 2017 BioInvent and the French biotech company Transgene initiated a partnership to develop new treatments for solid tumours.
Our tools for successful drug development
In an automated process, we select new drug candidates from our own antibody library – one of the largest in the world.
Our unique and patented development tool has the advantage of simultaneously identifying disease-associated targets and antibodies that bind to them.